Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study
复制标题
DOI：
10.21873/anticanres.15547
复制
发表时间：
2022-01
影响因子：
2
通讯作者：
A. Todaka;S. Nara;F. Motoi;S. Morinaga;Reishi Toshiyama;R. Higuchi;M. Konishi;H. Shirakawa;H. Tsu
中科院分区：
文献类型：
--
作者：
A. Todaka;S. Nara;F. Motoi;S. Morinaga;Reishi Toshiyama;R. Higuchi;M. Konishi;H. Shirakawa;H. Tsu
背景/目的：我们的目标是评估在改变辅助治疗后，腹膜灌洗细胞学阳性的胰腺癌(PC)的结果。患者和方法：收集并分析2007-2015年间14家医疗机构收治的胰腺癌患者的临床病理资料。结果：在124例符合条件的患者中，114例接受了宏观根治性切除。术后未复发80例(70%)，术后化疗：S一号43例(54%)，吉西他滨31例(39%)，其他6例(7%)。S一号组和吉西他滨组的中位总生存期分别为21.0个月和19.2个月(P=0.23)，无复发生存期分别为10.2个月和7.1个月(P=0.03)。结论：随着辅助治疗的改变，大部分接受肉眼根治性切除的Cy1期PC患者接受了S-1的治疗，但仍显不足。术后化疗尚需进一步发展。
Background/Aim: We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy. Patients and Methods: The clinicopathological data of patients with pancreatic adenocarcinoma with CY1 at 14 institutions, between 2007 and 2015, were collected and analyzed. Results: Of the 124 eligible patients, 114 underwent macroscopically curative resection. Of the 114 patients, 80 (70%) did not have early recurrence and received postoperative chemotherapy that was S-1 in 43 (54%), gemcitabine in 31 (39%), and others in six (7%). The median overall survival was 21.0 months in S-1 and 19.2 in gemcitabine therapy (p=0.23), whereas the median relapse-free survival was 10.2 and 7.1 months (p=0.03), respectively. Conclusion: Following the change in adjuvant therapy, most PC patients with CY1 who underwent macroscopically curative resection received S-1; however, it was insufficient. Further development of postoperative chemotherapy is required.